[go: up one dir, main page]

NO20073552L - Kombinasjoner av terapeutiske midler for behandling av kreft - Google Patents

Kombinasjoner av terapeutiske midler for behandling av kreft

Info

Publication number
NO20073552L
NO20073552L NO20073552A NO20073552A NO20073552L NO 20073552 L NO20073552 L NO 20073552L NO 20073552 A NO20073552 A NO 20073552A NO 20073552 A NO20073552 A NO 20073552A NO 20073552 L NO20073552 L NO 20073552L
Authority
NO
Norway
Prior art keywords
inhibitor
kinase inhibitor
cancer
combinations
treatment
Prior art date
Application number
NO20073552A
Other languages
English (en)
Inventor
Richard William Versace
Margaret Ma Woo
Sara Zaknoen
Claudio Pisano
Loredana Vesci
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36463409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073552(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20073552L publication Critical patent/NO20073552L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Kombinasjonsbehandling for å behandle pasienter som lider av proliferative sykdommer eller sykdommer assosiert med persistent angiogenese er beskrevet. Pasienten behandles med et kamptotecinderivat og et eller flere kjemoterapeutiske midler valgt fra et mikrotubult, aktivt middel; et alkylerende middel; en anti-neoplastisk antimetabolitt; en platinforbindelse; en topoisomerase 11-inhibitor; en VEGF-inhibitor; en tyrosinkinaseinhibitor; en EGFR-kinaseinhibitor; en mTOR-kinaseinhibitor; en insulinlignende vekstfaktor 1-inhibitor; en Raf-kinaseinhibitor; et monoklonalt antistoff, en proteasominhibitor; en HDAC-inhibitor og ioniserende stråling.
NO20073552A 2004-12-15 2007-07-09 Kombinasjoner av terapeutiske midler for behandling av kreft NO20073552L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63643904P 2004-12-15 2004-12-15
PCT/US2005/044993 WO2006065780A2 (en) 2004-12-15 2005-12-13 Combinations of therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
NO20073552L true NO20073552L (no) 2007-09-12

Family

ID=36463409

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073552A NO20073552L (no) 2004-12-15 2007-07-09 Kombinasjoner av terapeutiske midler for behandling av kreft

Country Status (26)

Country Link
US (1) US8975248B2 (no)
EP (1) EP1827437B1 (no)
JP (1) JP5345323B2 (no)
KR (1) KR101367516B1 (no)
CN (1) CN101080227B (no)
AT (1) ATE531371T1 (no)
AU (1) AU2005316652B2 (no)
BR (1) BRPI0515774A (no)
CA (1) CA2589521C (no)
CY (1) CY1112368T1 (no)
DK (1) DK1827437T3 (no)
ES (1) ES2374828T3 (no)
HR (1) HRP20110960T1 (no)
IL (1) IL183595A0 (no)
MA (1) MA29096B1 (no)
MX (1) MX2007007212A (no)
NO (1) NO20073552L (no)
NZ (1) NZ555370A (no)
PL (1) PL1827437T3 (no)
PT (1) PT1827437E (no)
RU (1) RU2400232C2 (no)
SI (1) SI1827437T1 (no)
TN (1) TNSN07224A1 (no)
TW (1) TW200628151A (no)
WO (1) WO2006065780A2 (no)
ZA (1) ZA200704701B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
US8975248B2 (en) 2004-12-15 2015-03-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
AU2006314444C1 (en) * 2005-11-21 2018-01-04 Novartis Ag Neuroendocrine tumor treatment using mTOR inhibitors
WO2007094026A1 (en) * 2006-02-17 2007-08-23 Paolo La Colla Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
EP2314297A1 (en) * 2006-04-05 2011-04-27 Novartis AG Combinations comprising bcr-abl/c-kit/pdgf-r tk inhibitors for treating cancer
CN101415409B (zh) * 2006-04-05 2012-12-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
US20090099103A1 (en) * 2006-04-05 2009-04-16 Novartis Ag. Combinations of therapeutic agents for treating cancer
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资（香港）有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
SI2786753T1 (sl) 2010-11-12 2019-05-31 Pharma Mar S.A. Kombinacijska terapija s protitumorskim antibiotikom
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
RU2693463C2 (ru) * 2014-04-04 2019-07-03 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, содержащее таксановое соединение и усилитель противоопухолевого эффекта
CN107847478A (zh) 2015-06-15 2018-03-27 新南部创新有限公司 有机氧化砷化合物和mTOR抑制剂的药物组合
CN107951888A (zh) * 2017-12-19 2018-04-24 天津科技大学 阿法替尼与10-羟基喜树碱的药物组合及其应用
CN109091480A (zh) * 2018-09-19 2018-12-28 天津科技大学 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途
BR112021011894A2 (pt) * 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN111789903A (zh) * 2019-04-08 2020-10-20 石小和 治疗尿道癌的药物组合物及其制备方法
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations
CN115814076A (zh) * 2021-07-01 2023-03-21 江苏先声药业有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
DE69531722T2 (de) 1994-11-11 2004-07-01 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US7105492B2 (en) 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
EP1044977B1 (en) * 1999-03-09 2002-05-02 Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Camptothecin derivatives having antitumor activity
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050038048A1 (en) 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US20040116407A1 (en) * 2002-07-11 2004-06-17 Alexis Borisy Combinations of drugs for the treatment of neoplasms
CN1791396A (zh) 2003-05-21 2006-06-21 诺瓦提斯公司 组蛋白脱乙酰基酶抑制剂与化疗剂的组合
WO2005117980A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
US8975248B2 (en) 2004-12-15 2015-03-10 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinations of therapeutic agents for treating cancer
JP4702322B2 (ja) 2006-12-14 2011-06-15 トヨタ自動車株式会社 内燃機関の制御装置

Also Published As

Publication number Publication date
EP1827437A2 (en) 2007-09-05
AU2005316652A1 (en) 2006-06-22
JP5345323B2 (ja) 2013-11-20
CA2589521C (en) 2014-04-01
ATE531371T1 (de) 2011-11-15
US20100028338A1 (en) 2010-02-04
PL1827437T3 (pl) 2013-06-28
WO2006065780A3 (en) 2006-08-17
KR20070091286A (ko) 2007-09-10
CN101080227A (zh) 2007-11-28
RU2400232C2 (ru) 2010-09-27
BRPI0515774A (pt) 2008-08-05
SI1827437T1 (sl) 2012-02-29
RU2007126978A (ru) 2009-01-27
TW200628151A (en) 2006-08-16
TNSN07224A1 (en) 2008-11-21
MA29096B1 (fr) 2007-12-03
CN101080227B (zh) 2011-08-31
HRP20110960T1 (hr) 2012-01-31
CA2589521A1 (en) 2006-06-22
MX2007007212A (es) 2007-11-07
NZ555370A (en) 2010-03-26
IL183595A0 (en) 2007-10-31
US8975248B2 (en) 2015-03-10
AU2005316652B2 (en) 2009-07-23
KR101367516B1 (ko) 2014-02-27
CY1112368T1 (el) 2015-12-09
DK1827437T3 (da) 2012-02-13
JP2008524225A (ja) 2008-07-10
ES2374828T3 (es) 2012-02-22
ZA200704701B (en) 2008-09-25
PT1827437E (pt) 2012-01-12
WO2006065780A2 (en) 2006-06-22
EP1827437B1 (en) 2011-11-02

Similar Documents

Publication Publication Date Title
NO20073552L (no) Kombinasjoner av terapeutiske midler for behandling av kreft
NO20061777L (no) Kombinasjon av en VEGF-resptorinhibitor og er kjemopteraputisk middel
Ferrario et al. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
ES2654623T3 (es) Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
US9439897B2 (en) Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
Wei et al. Effect of captopril on radiation-induced TGF-β1 secretion in EA. Hy926 human umbilical vein endothelial cells
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
Dougherty et al. Photoradiation therapy of human tumors
Agrawal et al. Brucine, a plant derived alkaloid inhibits inflammatory angiogenesis in a murine sponge model
RU99126204A (ru) Способ лечения рака легкого
JP2008516921A (ja) 多剤耐性の治療および予防
EA200970444A1 (ru) Способ введения противоопухолевого соединения
DE602004030545D1 (de) Behandlung proliferativer erkrankungen mit epothilon-derivaten und bestrahlung
RU2005110536A (ru) Способ лечения рака
Malik et al. CPQ Medicine (2018) 2: 2 Research Article
Tzerkovsky Photodynamic Therapy for Classic (Idiopathic) Type of Kaposi's Sarcoma (Case Report)
DK1687642T3 (da) Screeningsfremgangsmåder til kombinationer af biologiske forbindelser
EA202092513A1 (ru) Комбинированная терапия

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application